G Proteins in Cancer: The Prostate Cancer Paradigm

Sci. STKE, 20 January 2004
Vol. 2004, Issue 216, p. re2
DOI: 10.1126/stke.2162004re2

G Proteins in Cancer: The Prostate Cancer Paradigm

  1. Yehia Daaka*
  1. Department of Surgery and Pharmacology and Cancer Biology, Duke University Medical Center, Durham, NC 27710, USA.
  1. Contact information. DUMC 2607, Duke University Medical Center, Durham, NC 27710, USA. Telephone, 919-684-8440; fax, 919-684-9990; e-mail, daaka001{at}mc.duke.edu


Signal transduction research investigating mechanisms of androgen-independent prostate cancer cell proliferation has historically focused on the role of androgen and peptide growth factor receptors. More recent work has raised the idea that intracellular signaling mechanisms triggered by extracellular hormonal factors acting through heterotrimeric guanine nucleotide-binding protein (G protein)-coupled receptors (GPCRs) can also mediate and sustain this pathologic process. Prostate cancer patients with advanced disease express elevated levels of GPCRs and GPCR ligands, suggesting that the GPCR system is activated in the cancerous gland and may contribute to tumor growth. Importantly, inhibition of G protein signaling attenuates prostate cancer cell growth in animal models. The nature of intracellular signaling pathways mediating mitogenic effects of GPCRs in prostate cancer is poorly defined, although the G protein-dependent activation of the Ras-to-mitogen-activated protein kinase pathway has emerged as a critical regulatory event. Activated GPCRs may also exert their mitogenic effects in the prostate by activating the androgen receptor.


Y. Daaka, G Proteins in Cancer: The Prostate Cancer Paradigm. Sci. STKE 2004, re2 (2004).

G-Protein {beta}{gamma} Subunit Dimers Modulate Kidney Repair after Ischemia-Reperfusion Injury in Rats
S. M. White, L. M. North, E. Haines, M. Goldberg, L. M. Sullivan, J. D. Pressly, D. S. Weber, F. Park, and K. R. Regner
Mol. Pharmacol. 86, 369-377 (1 October 2014)

G Protein-Coupled Receptor Kinase GRK5 Phosphorylates Moesin and Regulates Metastasis in Prostate Cancer
P. K. Chakraborty, Y. Zhang, A. S. Coomes, W.-J. Kim, R. Stupay, L. D. Lynch, T. Atkinson, J. I. Kim, Z. Nie, Y. Daaka et al.
Cancer Res. 74, 3489-3500 (1 July 2014)

The Arf GAP AGAP2 interacts with {beta}-arrestin2 and regulates {beta}2-adrenergic receptor recycling and ERK activation
Y. Wu, Y. Zhao, X. Ma, Y. Zhu, J. Patel, and Z. Nie
Biochem. J. 452, 411-421 (15 June 2013)

G Protein-Coupled Receptor-Mediated Activation of p110{beta} by G{beta}{gamma} Is Required for Cellular Transformation and Invasiveness
H. A. Dbouk, O. Vadas, A. Shymanets, J. E. Burke, R. S. Salamon, B. D. Khalil, M. O. Barrett, G. L. Waldo, C. Surve, C. Hsueh et al.
Sci Signal 5, ra89-ra89 (4 December 2012)

Pharmacological Actions of Statins: A Critical Appraisal in the Management of Cancer
P. Gazzerro, M. C. Proto, G. Gangemi, A. M. Malfitano, E. Ciaglia, S. Pisanti, A. Santoro, C. Laezza, and M. Bifulco
Pharmacol. Rev. 64, 102-146 (1 January 2012)

Dissection of Aberrant GPCR Signaling in Tumorigenesis - A Systems Biology Approach
J. Wu, N. Xie, X. Zhao, E. C. Nice, and C. Huang
Cancer Genomics Proteomics 9, 37-50 (1 January 2012)

Disease-associated GPR56 Mutations Cause Bilateral Frontoparietal Polymicrogyria via Multiple Mechanisms
N.-Y. Chiang, C.-C. Hsiao, Y.-S. Huang, H.-Y. Chen, I.-J. Hsieh, G.-W. Chang, and H.-H. Lin
J Biol Chem 286, 14215-14225 (22 April 2011)

G{beta}{gamma} Signaling Promotes Breast Cancer Cell Migration and Invasion
J. K. Kirui, Y. Xie, D. W. Wolff, H. Jiang, P. W. Abel, and Y. Tu
J. Pharmacol. Exp. Ther. 333, 393-403 (1 May 2010)

Critical Role of G{alpha}12 and G{alpha}13 for Human Small Cell Lung Cancer Cell Proliferation In vitro and Tumor Growth In vivo
M. Grzelinski, O. Pinkenburg, T. Buch, M. Gold, S. Stohr, H. Kalwa, T. Gudermann, and A. Aigner
Clin. Cancer Res. 16, 1402-1415 (1 March 2010)

Identification of {beta}Arrestin2 as a corepressor of androgen receptor signaling in prostate cancer
V. Lakshmikanthan, L. Zou, J. I. Kim, A. Michal, Z. Nie, N. C. Messias, J. L. Benovic, and Y. Daaka
Proc. Natl. Acad. Sci. USA 106, 9379-9384 (9 June 2009)

The Glutamatergic System Expression in Human PC-3 and LNCaP Prostate Cancer Cells
Anticancer Res 29, 371-377 (1 January 2009)

2,2-Bis(4-Chlorophenyl)-1,1-Dichloroethylene Stimulates Androgen Independence in Prostate Cancer Cells through Combinatorial Activation of Mutant Androgen Receptor and Mitogen-Activated Protein Kinase Pathways
S. Shah, J. K. Hess-Wilson, S. Webb, H. Daly, S. Godoy-Tundidor, J. Kim, J. Boldison, Y. Daaka, and K. E. Knudsen
Mol Cancer Res 6, 1507-1520 (1 September 2008)

Vasoactive Intestinal Peptide Transactivates the Androgen Receptor through a Protein Kinase A-Dependent Extracellular Signal-Regulated Kinase Pathway in Prostate Cancer LNCaP Cells
Y. Xie, D. W. Wolff, M.-F. Lin, and Y. Tu
Mol. Pharmacol. 72, 73-85 (1 July 2007)

Ligand Binding to the Androgen Receptor Induces Conformational Changes That Regulate Phosphatase Interactions
C.-S. Yang, H.-W. Xin, J. B. Kelley, A. Spencer, D. L. Brautigan, and B. M. Paschal
Mol. Cell. Biol. 27, 3390-3404 (1 May 2007)

Differential targeting of Gbetagamma-subunit signaling with small molecules.
T. M. Bonacci, J. L. Mathews, C. Yuan, D. M. Lehmann, S. Malik, D. Wu, J. L. Font, J. M. Bidlack, and A. V. Smrcka
Science 312, 443-446 (21 April 2006)

Targeting Multiple Signaling Pathways as a Strategy for Managing Prostate Cancer: Multifocal Signal Modulation Therapy
M. F. McCarty, J. L. Mathews, C. Yuan, D. M. Lehmann, S. Malik, D. Wu, J. L. Font, J. M. Bidlack, and A. V. Smrcka
Integr Cancer Ther 3, 349-380 (1 December 2004)

Finding fusion genes resulting from chromosome rearrangement by analyzing the expressed sequence databases
Y. Hahn, T. K. Bera, K. Gehlhaus, I. R. Kirsch, I. H. Pastan, and B. Lee
Proc. Natl. Acad. Sci. USA 101, 13257-13261 (7 September 2004)

Science Signaling. ISSN 1937-9145 (online), 1945-0877 (print). Pre-2008: Science's STKE. ISSN 1525-8882